Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Clinical Trials

VOTRAGE

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

IVY

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Pazopanib and ARQ 197 for Advanced Solid Tumors

PazoX

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

DIET

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

HNSCC

Study To Assess Long Term Safety Of Pazopanib

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Pazopanib, Docetaxel, Prednisone Prostate

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

VEG111485: A QTc Study of Pazopanib

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

PATH

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

PAZPET-1

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

PASART-1